|
Video: What is a Stock Split?
|
|
Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. Co.'s main radiotherapeutic candidate, Rhenium-186 NanoLiposome is designed to target central nervous system cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access. Co.'s radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere is designed to treat various solid organ cancers including primary and secondary liver cancers. According to our PSTV split history records, Plus Therapeutics has had 2 splits. | |
|
Plus Therapeutics (PSTV) has 2 splits in our PSTV split history database. The first split for PSTV took place on August 06, 2019. This was a 1 for 50 reverse split, meaning for each 50 shares of PSTV owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split. PSTV's second split took place on May 01, 2023. This was a 1 for 15 reverse split, meaning for each 15 shares of PSTV owned pre-split, the shareholder now owned 1 share. For example, a 20 share position pre-split, became a 1.33333333333333 share position following the split.
When a company such as Plus Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PSTV split history from start to finish, an original position size of 1000 shares would have turned into 1.33333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Plus Therapeutics shares, starting with a $10,000 purchase of PSTV, presented on a split-history-adjusted basis factoring in the complete PSTV split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$1,957.50 |
|
End price/share: |
$1.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.91% |
|
Average Annual Total Return: |
-50.40% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9.05 |
|
Years: |
9.99 |
|
|
|
Date |
Ratio |
08/06/2019 | 1 for 50 | 05/01/2023 | 1 for 15 |
|
|